{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:26:40Z","timestamp":1784752000971,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27043","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T22:18:29Z","timestamp":1709590709000},"page":"e27043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The therapeutic landscape for COVID-19 and post-COVID-19 medications from genetic profiling of the Vietnamese population and a predictive model of drug-drug interaction for comorbid COVID-19 patients"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1577-380X","authenticated-orcid":false,"given":"Thien Khac","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-9736","authenticated-orcid":false,"given":"Giang Minh","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5431-6500","authenticated-orcid":false,"given":"Vinh Chi","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-7450","authenticated-orcid":false,"given":"Thang Luong","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang Thi Ha","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Hoang","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duong Thuy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-9176","authenticated-orcid":false,"given":"Nam S.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-5983","authenticated-orcid":false,"given":"Huong Thanh","family":"Phung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-237X","authenticated-orcid":false,"given":"Tham Hong","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e27043_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.699321","article-title":"Changes in the proportion of gastrointestinal emergency endoscopy and peptic ulcer disease during the COVID-19 pandemic: a local retrospective observational study from Vietnam","volume":"10","author":"Dao","year":"2022","journal-title":"Front. Public Health"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27043_bib2","first-page":"86","article-title":"Impact of COVID-19 pandemic on chronic diseases care follow-up and current perspectives in low resource settings: a narrative review","volume":"13","author":"Fekadu","year":"2021","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"10.1016\/j.heliyon.2024.e27043_bib3","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.."},{"key":"10.1016\/j.heliyon.2024.e27043_bib4","series-title":"The 8th Guidelines for Diagnosis and Treatment COVID-19","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e27043_bib5","unstructured":"Therapeutics and COVID-19: living guideline, 16 September 2022. Geneva: World Health Organization, (WHO\/2019-nCoV\/therapeutics\/2022.5) (2022)."},{"issue":"728","key":"10.1016\/j.heliyon.2024.e27043_bib6","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3399\/BJGP.2022.0181","article-title":"Adverse drug reactions and associated patient characteristics in older community-dwelling adults: a 6-year prospective cohort study","volume":"73","author":"Doherty","year":"2023","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.heliyon.2024.e27043_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.602841","article-title":"Incidence of suspected serious adverse drug reactions in corona virus disease-19 patients detected by a pharmacovigilance program by laboratory signals in a tertiary hospital in Spain: cautionary data","volume":"11","author":"Ram\u00edrez","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27043_bib8","article-title":"Adverse drug reactions in patients with COVID-19 in Brazil: analysis of spontaneous notifications of the Brazilian pharmacovigilance system","volume":"37","author":"Melo","year":"2021","journal-title":"Cad. Sa\u00fade P\u00fablica"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27043_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.705","article-title":"Drug-drug interactions with candidate medications used for COVID-19 treatment: an overview","volume":"9","author":"Rezaee","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27043_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048391","article-title":"Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study","volume":"11","author":"Dennis","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2024.e27043_bib11","series-title":"The Guidelines Vietnam Ministry of Health for Diagnosis and Treatment Post COVID-19 for Adults","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e27043_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.835136","article-title":"Pharmacogenetics and precision medicine approaches for the improvement of COVID-19 therapies","volume":"13","author":"Biswas","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e27043_bib13","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27043_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/v13030413","article-title":"Pharmacogenetics approach for the improvement of COVID-19 treatment","volume":"13","author":"Fricke-Galindo","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27043_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41397-021-00209-9","article-title":"Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs","volume":"21","author":"Badary","year":"2021","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27043_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41525-020-00143-y","article-title":"Pharmacogenomics of COVID-19 therapies","volume":"5","author":"Takahashi","year":"2020","journal-title":"npj Genomic Medicine"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27043_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/pgs-2021-0028","article-title":"Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes","volume":"22","author":"Sahana","year":"2021","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27043_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajhg.2018.11.014","article-title":"Integrating genomics into healthcare: a global responsibility","volume":"104","author":"Stark","year":"2019","journal-title":"Am. J. Hum. Genet."},{"issue":"7571","key":"10.1016\/j.heliyon.2024.e27043_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"7809","key":"10.1016\/j.heliyon.2024.e27043_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e27043_bib21","series-title":"Clinical Management of COVID-19: Living Guideline, 15 September 2022","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e27043_bib22","series-title":"Clinical Guidelines, COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e27043_bib23","series-title":"The Guidelines of Vietnam Ministry of Health for Diagnosis and Treatment Post COVID-19 for Children at Home","year":"2022"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27043_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27043_bib25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27043_bib26","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/cpt.1552","article-title":"Calling star alleles with stargazer in 28 pharmacogenes with whole genome sequences","volume":"106","author":"Lee","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"30","key":"10.1016\/j.heliyon.2024.e27043_bib27","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1073\/pnas.1707945114","article-title":"Fast and accurate HLA typing from short-read next-generation sequence data with xHLA","volume":"114","author":"Xie","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"Database issue","key":"10.1016\/j.heliyon.2024.e27043_bib28","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e27043_bib29","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1093\/nar\/gkg509","article-title":"SIFT: predicting amino acid changes that affect protein function","volume":"31","author":"Ng","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.heliyon.2024.e27043_bib30","article-title":"Predicting functional effect of human missense mutations using PolyPhen-2","volume":"7","author":"Adzhubei","year":"2013","journal-title":"Curr Protoc Hum Genet Chapter"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27043_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat. Methods"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27043_bib32","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jiph.2020.07.014","article-title":"COVID-19 and comorbidities: deleterious impact on infected patients","volume":"13","author":"Ejaz","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.heliyon.2024.e27043_bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jbi.2017.04.021","article-title":"Computational prediction of drug-drug interactions based on drugs functional similarities","volume":"70","author":"Ferdousi","year":"2017","journal-title":"J. Biomed. Inf."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27043_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00602-21","article-title":"Key metabolic enzymes involved in remdesivir activation in human lung cells","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27043_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97160-3","article-title":"Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics","volume":"11","author":"Ambrus","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27043_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010039","article-title":"A human ABC transporter ABCC4 gene SNP (rs11568658, 559 G > T, G187W) reduces ABCC4-dependent drug resistance","volume":"8","author":"Tsukamoto","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27043_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/14622416.9.5.597","article-title":"Pharmacogenetics of OATP (SLC21\/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney","volume":"9","author":"Za\u00efr","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e27043_bib38","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/blood-2013-05-501692","article-title":"Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces","volume":"122","author":"Czogalla","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e27043_bib39","first-page":"47","article-title":"VKORC1 variants as significant predictors of warfarin dose in Emiratis","volume":"12","author":"Al-Mahayri","year":"2019","journal-title":"Pharmgenomics Pers Med"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e27043_bib40","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddi180","article-title":"A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity","volume":"14","author":"Yuan","year":"2005","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27043_bib41","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1124\/mol.109.054833","article-title":"CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant","volume":"75","author":"McDonald","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27043_bib42","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","article-title":"CYP4F2 genetic variant alters required warfarin dose","volume":"111","author":"Caldwell","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27043_bib43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27043_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27043_bib45","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","article-title":"Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions","volume":"25","author":"Kongpan","year":"2015","journal-title":"Pharmacogenetics Genom."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27043_bib46","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/cpt.1915","article-title":"Genetic association of Co-Trimoxazole-Induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes","volume":"108","author":"Sukasem","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27043_bib47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/toxsci\/kfq361","article-title":"Phospholipidosis induced by PPAR\u03b3 signaling in human bronchial epithelial (BEAS-2B) cells exposed to amiodarone","volume":"120","author":"Song","year":"2011","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.heliyon.2024.e27043_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3389\/fphar.2019.01045","article-title":"Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): management of extrapyramidal side effects","volume":"10","author":"Ohno","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27043_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.06.015","article-title":"Multidrug resistance-associated protein 4 in pharmacology: overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics","volume":"231","author":"Berthier","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2024.e27043_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vph.2015.06.016","article-title":"Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets","volume":"76","author":"Temperilli","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27043_bib51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphar.2015.00013","article-title":"Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets","volume":"6","author":"Pastor-Anglada","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27043_bib52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2014.03.005","article-title":"Involvement of organic cation transporter 2 inhibition in potential mechanisms of antidepressant action","volume":"53","author":"Wang","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e27043_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.491895","article-title":"How can drug metabolism and transporter genetics inform psychotropic prescribing?","volume":"11","author":"Carvalho Henriques","year":"2020","journal-title":"Front. Genet."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27043_bib54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FPC.0b013e3283482502","article-title":"The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers","volume":"21","author":"Yamada","year":"2011","journal-title":"Pharmacogenetics Genom."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27043_bib55","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1124\/mol.107.035550","article-title":"Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor","volume":"72","author":"Lakhman","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27043_bib56","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27043_bib57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27043_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27043_bib59","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1398-9995.2009.02048.x","article-title":"The HLA allele marker for differentiating ASA hypersensitivity phenotypes","volume":"64","author":"Lee","year":"2009","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27043_bib60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425255.2021.1876661","article-title":"ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?","volume":"17","author":"Bruckmueller","year":"2021","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27043_bib61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.heliyon.2024.e27043_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.938552","article-title":"Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system","volume":"13","author":"Jeong","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27043_bib63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41397-022-00289-1","article-title":"Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach","volume":"22","author":"Charitou","year":"2022","journal-title":"Pharmacogenomics J."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024030743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024030743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:39:31Z","timestamp":1782247171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024030743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024030743"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27043","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic landscape for COVID-19 and post-COVID-19 medications from genetic profiling of the Vietnamese population and a predictive model of drug-drug interaction for comorbid COVID-19 patients","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27043"}}